En undersøgelse, der vurderer esophageal funktion og ombygning med Dupilumab sammenlignet med placebo i 24 uger efterfulgt af 104 ugers åben etiket hos voksne deltagere med EoE (REMODELING med Dupilumab i langtidsforsøg med eosinofil øsofagitis)
Et fase 4, randomiseret, multicenter, dobbeltblindt, parallel-gruppe, 24 uger, placebokontrolleret undersøgelse efterfulgt af 104 uger åbent til vurdering af Dupilumabs effekt på esophageal funktion og ombygning hos voksne deltagere med eosinofil esophagitis (EoE)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
- Screening period: Up to 12 weeks before Week 0
- Randomized double-blind period: 24 weeks
- Open label period: 104 weeks
- Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.
There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The duration per participant will be up to 152 weeks.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
São Paulo, Brasilien, 01323-020
- Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41825-010
- Itaigara Memorial - Hospital Dia- Site Number : 0760005
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
-
-
São Paulo
-
Campinas, São Paulo, Brasilien, 13010-001
- Clínica Loema - Unidade I- Site Number : 0760007
-
Sorocaba, São Paulo, Brasilien, 18040-425
- Clinica de Alergia Martti Antila- Site Number : 0760001
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Investigational Site Number : 1240006
-
Vancouver, British Columbia, Canada, V6Z 2K5
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3T2
- Investigational Site Number : 1240002
-
-
-
-
California
-
Murrieta, California, Forenede Stater, 92563
- United Gastroenterologists - Murrieta- Site Number : 8400001
-
San Francisco, California, Forenede Stater, 94143
- University of California San Francisco - Parnassus Heights- Site Number : 8400020
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32256
- Borland Groover Clinic- Site Number : 8400016
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Treasure Valley Medical Research- Site Number : 8400018
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University- Site Number : 8400003
-
Glenview, Illinois, Forenede Stater, 60026
- GI Alliance - Glenview- Site Number : 8400012
-
Gurnee, Illinois, Forenede Stater, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa- Site Number : 8400006
-
-
Massachusetts
-
Worcester, Massachusetts, Forenede Stater, 01655
- University of Massachusetts Chan Medical School- Site Number : 8400019
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Hospital Rochester- Site Number : 8400008
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- University of North Carolina at Chapel Hill- Site Number : 8400007
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400009
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
-
-
Texas
-
Houston, Texas, Forenede Stater, 77087
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015
-
Mansfield, Texas, Forenede Stater, 76063
- GI Alliance - Mansfield- Site Number : 8400017
-
-
-
-
-
Haifa, Israel, 3104802
- Investigational Site Number : 3760006
-
Haifa, Israel, 3109601
- Investigational Site Number : 3760002
-
Jerusalem, Israel, 9103102
- Investigational Site Number : 3760005
-
Jerusalem, Israel, 9112001
- Investigational Site Number : 3760004
-
Tel Aviv, Israel, 6423906
- Investigational Site Number : 3760003
-
-
-
-
-
Wetzikon, Schweiz, 8620
- Investigational Site Number : 7560001
-
Zurich, Schweiz, 8091
- Investigational Site Number : 7560002
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- A documented diagnosis of EoE by endoscopic biopsy.
- Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
- History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
- Body weight ≥40 kg.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
- Active Helicobacter pylori infection.
- History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
- Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
- History of bleeding disorders or esophageal varices.
- Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.
- Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
- Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
SC injection as per protocol |
SC injection as per protocol |
|
Eksperimentel: Dupilumab
Subcutaneous injection (SC) as per protocol |
Subcutaneous injection (SC) as per protocol |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Tidsramme: From baseline to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline to Week 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af behandlingsfremkomne bivirkninger (TEAE'er) og alvorlige bivirkninger (SAE'er)
Tidsramme: Fra den første IMP-administration til slutningen af opfølgningsperioden efter behandling (uge 139)
|
Fra den første IMP-administration til slutningen af opfølgningsperioden efter behandling (uge 139)
|
|
|
Forekomst af bivirkninger af særlig interesse (AESI'er)
Tidsramme: Fra den første IMP-administration til slutningen af opfølgningsperioden efter behandling (uge 139)
|
Fra den første IMP-administration til slutningen af opfølgningsperioden efter behandling (uge 139)
|
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsramme: From baseline up to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week 24
|
|
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsramme: From baseline up to Week128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week128
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsramme: From Baseline up to Week 128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From Baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)
Tidsramme: From baseline up to Week 128
|
EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease. |
From baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
Tidsramme: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Change from baseline in EoE-HSS Stage
Tidsramme: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)
Tidsramme: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF
Tidsramme: At Week 24
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Week 24
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF
Tidsramme: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature
Tidsramme: From baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From baseline up to Week 128 (EOT)
|
|
Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature
Tidsramme: From Baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From Baseline up to Week 128 (EOT)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Clinical Sciences & Operations, Sanofi
Publikationer og nyttige links
Generelle publikationer
- Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simoes Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.
- Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- LPS17558
- U1111-1280-5266 (Registry Identifier: ICTRP)
- 2022-502491-23 (Registry Identifier: CTIS)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .